Medical triple net lease fund · Series 3 now open
Four ways to work with us
More than a fund. A platform
with four capabilities.
Our portfolio
A track record and portfolio
Buildings
84
States
27
Assets Under Management
$150M+
- Annual NOI
$10.3M
Our Offerings
7–8%
Average cash-on-cash
2.0x
Equity multiple
16–20%
Targeted IRR
25%–35%
Targeted IRR (upside)
5 Years
Holding Period
Targets are not guaranteed and actual results may differ. Past performance does not predict future results. Offered under Regulation D 506(c) to accredited investors only.
Find your Fit
Three Paths to Invest With Us
Targets are not guaranteed and actual results may differ. Past performance does not predict future results. Offered under Regulation D 506(c) to accredited investors only.
The Thesis
Three Paths to Invest With Us
Factor
Who pays expenses
Lease length
Tenant
Inflation protection
Tenant turnover
Management intensity
Triple-net medical
Tenant pays taxes, insurance & maintenance (NNN)
10–15 years standard
Healthcare operators, many PE-backed
2–3% annual rent escalations built into the lease
Low — costly specialised build-outs keep tenants in place
Light — one tenant per building
Multifamily
Landlord absorbs operating costs
1–2 years standard
Individual households
Mark-to-market at renewal
Higher turnover is common
Heavy many units, many tenants
Investor’s Stories
Hear from the people investing alongside us.
From healthcare professionals to experienced executives, our investors value a disciplined approach to medical real estate, transparent communication, and a long-term partnership.
Testimonials reflect the individual experiences of current investors and may not be representative of other investors’ experiences.
Targets are not guaranteed and actual results may differ. Past performance does not predict future results. Offered under Regulation D 506(c) to accredited investors only.
See your projected returns.
An illustration at the fund's target range (Series 3). Not a forecast or a promise of returns.
(cost segregation, ~60% of investment)
at 7% target
over the hold
(capital + appreciation)
Targets are not guaranteed and actual results may differ. Past performance does not predict future results. Offered under Regulation D 506(c) to accredited investors only.




